SCEL: A Potential Drug Target and Biomarker for T-Cell Development and Function

Target Name: SCEL

NCBI ID: G8796

SCEL

SCEL: A Potential Drug Target and Biomarker for T-Cell Development and Function

SCEL, or Sciellin, transcript variant 1, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the T-cell receptor (TCR) family, which is a protein that is responsible for cell-mediated immunity.

SCEL is known for its role in the regulation of T-cell development and function. It has been shown to play a key role in the development of T-cell exhaustion, which is a condition in which T-cells are no longer able to recognize and respond to antigens. This is thought to contribute to the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.

In addition to its role in T-cell development and regulation, SCEL has also been shown to play a potential role as a drug target. Several studies have shown that inhibiting the activity of SCEL has the potential to treat a variety of diseases, including autoimmune diseases, cancer, and neurodegenerative diseases.

One of the potential mechanisms by which SCEL may be targeted with drugs is its role in the regulation of the immune response. As mentioned earlier, SCEL is involved in the regulation of T-cell development and function, and has been shown to play a key role in the development of T-cell exhaustion. By inhibiting the activity of SCEL, researchers may be able to treat T-cell exhaustion-related diseases, such as autoimmune diseases.

Another potential mechanism by which SCEL may be targeted with drugs is its role in the regulation of cell survival. SCEL has been shown to play a role in the regulation of cell survival and has been shown to be involved in the development of cancer. By inhibiting the activity of SCEL, researchers may be able to treat a variety of cancers.

In addition to its potential as a drug target, SCEL is also of interest as a biomarker. Because SCEL is expressed in a variety of tissues and is involved in the regulation of T-cell development and function, it has been suggested as a potential biomarker for a variety of diseases, including cancer and autoimmune diseases.

Overall, SCEL is a protein that has the potential to be a drug target or biomarker. Further research is needed to fully understand its role in the regulation of T-cell development and function, as well as its potential as a drug or biomarker.

Protein Name: Sciellin

Functions: May function in the assembly or regulation of proteins in the cornified envelope. The LIM domain may be involved in homotypic or heterotypic associations and may function to localize sciellin to the cornified envelope

The "SCEL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCEL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets